FRANKFURT (dpa-AFX) - Morphosys shares reacted to sales forecasts for the important blood cancer drug Monjuvi with significant price losses on Thursday. The share price last sank by 7.4 percent to 13.30 euros. After high price losses in the fall of 2022, the papers had recently stabilized above 12 euros.

The company expects only small growth at best for Monjuvi this year. It forecast net product sales of $80 million to $95 million.

The midpoint of this range is 20 percent below the average expectation of analysts, JPMorgan noted. The consensus estimate is now expected to fall by that 20 percent. The maximum sales potential of 500 to 750 million euros that Monjuvi had promised is now also probably no longer realistic./bek/jha/